<DOC>
	<DOC>NCT00207701</DOC>
	<brief_summary>A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis</brief_summary>
	<brief_title>A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.</brief_title>
	<detailed_description>This is a clinical research study that will determine if there is a reduction in the signs and symptoms (such as back pain and stiffness) of patients with ankylosing spondylitis with infliximab therapy. This study will also study the safety of infliximab in patients with ankylosing spondylitis. The effect of infliximab on physical function, damage to joints and the quality of life in patients with ankylosing spondylitis will also be studied. Subjects received infusions of either placebo at weeks 0, 2, 6, 12, 18 and 5 mg/kg infliximab at weeks 24, 26, 30 and every 6 weeks through week 96, or 5 mg/kg infliximab at weeks 1, 2, 6, 12, 18 and every 6 weeks through week 96</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Have had a diagnosis of definite Akylosing Spondylitis for at least 3 months prior to screening Have active disease with spinal pain receiving or intolerant to standard antiinflammatory agents Have Rheumatoid Arthritis, systemic lupus erythematosus, or other inflammatory rheumatic disease Have a documented history of fibromyalgia Have total ankylosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>infusion</keyword>
</DOC>